Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-25T22:33:56.756Z Has data issue: false hasContentIssue false
  • English
  • Français

The neuropsychological consequences of cannabis use in schizophrenia: a preliminary analysis

Published online by Cambridge University Press:  24 June 2014

K Croaker ,
R Langdo  and
P Ward
K Croaker
Affiliation:
Schizophrenia Research Unit, Liverpool Hospital Macquarie University
R Langdo
Affiliation:
Schizophrenia Research Unit, Liverpool Hospital Macquarie Centre for Cognitive Science
P Ward
Affiliation:
Schizophrenia Research Unit, Liverpool Hospital School of Psychiatry, University of New South Wales, Sydney, Australia
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Abstracts from ‘Brainwaves’— The Australasian Society for Psychiatric Research Annual Meeting 2006, 6–8 December, Sydney, Australia
Information
Acta Neuropsychiatrica , Volume 18 , Issue 6 , December 2006 , pp. 282
Copyright
Copyright © 2006 Blackwell Munksgaard

Background:

There has been considerable controversy regarding the possible causal role of cannabis use in the development of schizophrenia; there have also been contradictory findings concerning the impact of cannabis use on neuropsychological function in schizophrenia and in non-psychiatric samples. This paper presents preliminary data comparing neuropsychological task performances of people with a diagnosis of schizophrenia with and without cannabis use.

Methods:

Participants included 17 individuals with a diagnosis of schizophrenia (10 without cannabis use, plus 3 with current cannabis use, combined with 4 for whom cannabis use was significant at onset but is no longer in use, to make the 7 members of the cannabis-using group). All participants were tested on neuropsychological measures covering a range of cognitive domains (executive functioning, memory, learning, attention and information processing speed). Psycho-pathological assessments (eg depression, symptom ratings) and detailed drug use measures were also conducted.

Results:

The cannabis-using group was more symptomatic, had lower levels of current intelligence and showed greater impulsivity as indexed by the CPT, compared with the non-cannabis-using group. There were trends toward greater recognition memory deficits and arousal deficits as indexed by the CPT in the cannabis-using group.

Conclusions:

Cannabis use in schizophrenia may be associated with greater symptom severity and increased deficits in impulse control and current intelligence. Although preliminary, these results are inconsistent with the self-medication hypothesis, as symptoms are exacerbated by cannabis.